You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.

Tag:

Metastasis x

Anti-estrogen therapies, such as tamoxifen and aromatase inhibitors, are standard therapy for breast cancers that depend on estrogen for growth – known as estrogen receptor-positive (ER+).

While much progress has been made in the treatment of breast cancer over the last 25 years, much work remains. New treatments are urgently needed for patients with metastatic breast cancer, triple-negative breast cancer and breast cancers that do not respond to currently available treatments, or

The Metastatic Breast Cancer Project (MBCProject.org) is a collaborative new research project launched by the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute that directly engages metastatic breast cancer patients and empowers them to ac

Rebecca Scheinkman was six days shy of her 33rd birthday when learned she had metastatic breast cancer. While the diagnosis came as a shock, she turned to her past for support. At 14 years old, she was diagnosed and successfully treated for acute lymphoblastic leukemia.

Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain.

This blog was written by Zoë Mintz, BCRF's Manager of Digital Communications

When Rochelle Barr first heard the words “triple negative breast cancer,” she was optimistic about her prognosis. After all, in the medical world, testing negative is usually considered a good thing.

A blood-based test, measuring what is called cell-free DNA in blood plasma, identified mutations in the estrogen receptor gene, called ESR1, in 30